PMID- 16471313
OWN - NLM
STAT- MEDLINE
DCOM- 20060601
LR  - 20131121
IS  - 0392-9078 (Print)
IS  - 0392-9078 (Linking)
VI  - 24
IP  - 4
DP  - 2005 Dec
TI  - Efficacy of Helicobacter pylori eradication on the chronic mucosal inflammation 
      of the remnant stomach after distal gastrectomy for early gastric cancer.
PG  - 515-21
AB  - Although eradication of Helicobacter pylori (Hp) after early gastric carcinoma 
      has been recommended, very limited studies have been reported and the method 
      differs from standard therapy. Here, we attempted the eradication of Hp in the 
      remnant stomach after surgery for primary gastric cancer with the standardized 
      method. We examined efficacy and the safeness of the treatment. Thirty-three H. 
      pylori-positive patients after distal gastrectomy were treated with proton pump 
      inhibitor (PPI)-based triple therapies. After eradication, endoscopic and 
      histological changes were classified on the basis of the Updated Sydney System. 
      The eradication rate in the remnant stomach was 90.9% (30 out of 33 cases) after 
      triple therapy. Temporal minor side effects were notified in 3 cases. After 
      eradication, the remnant stomach showed significant decreases in inflammation- 
      and activity-scores. Moreover, significant improvement in glandular atrophy to 
      normal mucosa was found. In conclusion, PPI-based standard therapy is just as 
      effective for Hp eradication in the remnant stomach than it is in the 
      non-operative stomach. Eradication therapy could be performed safely and resulted 
      in a significant improvement in inflammation and atrophy of the mucosal layer in 
      the remnant stomach after early gastric cancer surgery.
FAU - Onoda, N
AU  - Onoda N
AD  - Dept. of Oncology, Institute of Geriatrics and Medical Science, Osaka City 
      University Graduate School of Medicine, Japan. nonoda@med.osaka-cu.ac.jp
FAU - Katsuragi, K
AU  - Katsuragi K
FAU - Sawada, T
AU  - Sawada T
FAU - Maeda, K
AU  - Maeda K
FAU - Mino, A
AU  - Mino A
FAU - Ohira, M
AU  - Ohira M
FAU - Ishikawa, T
AU  - Ishikawa T
FAU - Wakasa, K
AU  - Wakasa K
FAU - Hirakawa, K
AU  - Hirakawa K
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Exp Clin Cancer Res
JT  - Journal of experimental & clinical cancer research : CR
JID - 8308647
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Anti-Infective Agents)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Benzimidazoles)
RN  - 140QMO216E (Metronidazole)
RN  - 32828355LL (Rabeprazole)
RN  - 804826J2HU (Amoxicillin)
RN  - KG60484QX9 (Omeprazole)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles
MH  - Adult
MH  - Aged
MH  - Amoxicillin/therapeutic use
MH  - Anti-Infective Agents/therapeutic use
MH  - Anti-Ulcer Agents/therapeutic use
MH  - Benzimidazoles/therapeutic use
MH  - Drug Therapy, Combination
MH  - Endoscopy, Digestive System
MH  - Female
MH  - Gastrectomy
MH  - Gastric Mucosa/*drug effects/microbiology/pathology
MH  - Gastric Stump/*pathology
MH  - Gastritis/*drug therapy/microbiology/pathology
MH  - Helicobacter Infections/*drug therapy
MH  - Helicobacter pylori
MH  - Humans
MH  - Male
MH  - Metronidazole/therapeutic use
MH  - Middle Aged
MH  - Omeprazole/analogs & derivatives/therapeutic use
MH  - Rabeprazole
MH  - Stomach Neoplasms/*pathology/surgery
EDAT- 2006/02/14 09:00
MHDA- 2006/06/02 09:00
CRDT- 2006/02/14 09:00
PHST- 2006/02/14 09:00 [pubmed]
PHST- 2006/06/02 09:00 [medline]
PHST- 2006/02/14 09:00 [entrez]
PST - ppublish
SO  - J Exp Clin Cancer Res. 2005 Dec;24(4):515-21.